← Research library

Oral Chitomur versus capsule placebo in men with benign prostatic hyperplasia

Randomized study in people · 2013

What was studied
50 men aged 62–83 with benign prostatic hyperplasia. Chitomur 30, capsule placebo 20.
Main finding
Post-course peak urinary flow was 12.7 vs 9.4 mL/s and prostate symptom scores were 13.2 vs 15.6 with Chitomur versus placebo. Prostate volume showed no significant change.

Chitomur versus placebo. One month later, 10.36 vs 8.3 mL/s. · Table 1 marks p < 0.001 versus placebo at the post-course visit only.

Reported findings and study design

Chitomur 30 versus capsule placebo 20. Uroflowmetry, post-void residual volume, prostate ultrasound, and IPSS and quality-of-life questionnaires.

Population or model 50 men aged 62–83 with benign prostatic hyperplasia. Chitomur 30, capsule placebo 20.

Dose, route and schedule

Two 10 mg capsules twice daily with meals for 15 days (40 mg/day as reported). The comparator received placebo capsules. Methods place the post-course visit on day 16. The results narrative also uses day 14.

Protocol source ↗ · Russian full-article reproduction, methods and Tables 1–2. Indexed citation and abstract cross-checked. The indexed second-author initials differ from the reproduction.

Results · Russian full-article reproduction, methods and Tables 1–2. Indexed citation and abstract cross-checked. The indexed second-author initials differ from the reproduction.
MeasureResultComparison, timing and statistics
Peak urinary flow · post-course12.7 vs 9.4 mL/sChitomur versus placebo. One month later, 10.36 vs 8.3 mL/s. · Table 1 marks p < 0.001 versus placebo at the post-course visit only.
Post-void residual urine · post-course23.2 vs 72.1 mLOne month later, 48.7 vs 69.8 mL. · Table 1 marks p < 0.001 versus placebo at both times.
International Prostate Symptom Score · post-course13.2 vs 15.6 pointsOne month later, 15.7 vs 17.9. The table gives a single 17.4-point baseline. · Table 2 marks p < 0.001 versus placebo at the post-course visit only.
Prostate volume and mean flowNo significant prostate-volume changeThe table gives no significance marker for mean urinary flow.
Adverse eventsNone reported among Chitomur recipientsThe paper gives no systematic harms table.
Tables 1–2 · urinary measures by visit
Tables 1–2 · urinary measures by visit
MeasureSingle baseline columnChitomur post-coursePlacebo post-courseChitomur one month laterPlacebo one month later
Peak flow (mL/s)8.9 ± 0.812.7 ± 0.89.4 ± 1.410.36 ± 0.98.3 ± 1.7
Mean flow (mL/s)4.1 ± 0.74.7 ± 1.34.2 ± 1.64.4 ± 1.53.9 ± 1.7
Residual urine (mL)77.4 ± 16.123.2 ± 8.972.1 ± 19.248.7 ± 10.569.8 ± 13.7
IPSS17.4 ± 0.913.2 ± 1.215.6 ± 2.215.7 ± 1.117.9 ± 3.1
Quality-of-life index3.3 ± 0.22.4 ± 0.32.9 ± 0.52.8 ± 0.33.2 ± 0.6

Printed means and ± terms. The report gives one baseline column and inconsistent post-course timing. Peak flow and IPSS moved back toward baseline at follow-up.

The small study reported differences in urinary symptoms and function; prostate size did not measurably change. The conflict about masking limits confidence.

Source for these results ↗ · Reviewed 2026-11-14

Study limitations and source details

Study limitations

  • Methods describe a blinded randomized study and the conclusion calls it open. The accessible report does not explain concealment, masking or placebo contents.
  • Tables use a single baseline column and the reported endpoint timing varies. The sample and follow-up are too limited to characterize uncommon harms.

Source details

Journal article — commercial reproduction

Russian full-article reproduction, methods and Tables 1–2. Indexed citation and abstract cross-checked. The indexed second-author initials differ from the reproduction.

Methods and numerical tables checked

Sources checked

Citation

Randomized trialFull text available

V. G. Gomberg, A. P. Ryzhak, R. V. Lyutov. Oral Chitomur versus capsule placebo in men with benign prostatic hyperplasia Advances in Gerontology / Uspekhi Gerontologii. 2013;26(3):476–480. PMID 24640697.

Study source ↗ · Bibliography entry · Link to this summary

Related compounds

Editorial policy and evidence standards